Fundamental company data provided by Morningstar, updated daily. Stock quotes provided by InterActive Data. The gurus listed in this website are not affiliated with, LLC. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Past performance is a poor indicator of future performance. In no event shall be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on, or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Gurus may be added or dropped from the GuruFocus site at any time. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. This investment adviser does not provide advice to individual investors. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. is not operated by a broker or a dealer. The stock has a market cap of 636.46 million, a price-to-earnings ratio of -2.15 and a. has a 52 week low of 4.02 and a 52 week high of 43.12. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. The company’s 50 day moving average price is 8.25 and its 200-day moving average price is 18.55. On the date of publication, Eddie Pan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. Finally, FATE stock has an average price target of $76.30 among 20 firms with coverage of shares.Darout believes Fate’s current valuation offers “meaningful upside” and hopes to hear more updates during the second half of the year. Still, the analyst has questions on whether engineered NK cells can demonstrate convenience and safety for a hospital setting. Analyst Etzer Darout is a big fan of the company’s iPSC platform due to its “versatile off-the-shelf products” and unique position in the cell therapy space. BMO Capital has a price target of $47.As part of the collaboration, Fate will receive research funding, clinical and regulatory milestone payments and the “right to jointly develop and commercialize in the US and EU.” Goldstein views the extended collaboration as a sign of progress. Analyst Mara Goldstein raised her price target after Fate expanded its collaboration with Ono. Mizuho Securities has a price target of $109 for FATE stock.But how does the rest of Wall Street view Fate Therapeutics? Analysts Chime In on Fate Therapeutics While Fate still remains unprofitable, the seven proprietary cell therapy candidates in the company’s pipeline offer investors a chance to buy in on future potential. These recent purchases are Ark’s first since Feb. In ARKG, it is now the seventh-largest holding out of 49 total. After the two purchases, FATE stock is now the 17th largest holding among all Ark ETFs out of 51 total positions. It seems that Cathie Wood has had a change of heart ARKK sold 307,711 shares of FATE on Aug. On the same day, the ARK Genomic Revolution ETF (BATS: ARKG) also purchased 149,304 shares. Yesterday, the ARK Innovation ETF (NYSEARCA: ARKK) reported purchasing 478,756 shares of FATE stock.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |